Literature DB >> 8321047

Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells.

T Miyagi1, H Ahuja, T Kubota, I Kubonishi, H P Koeffler, I Miyoshi.   

Abstract

Wilms' tumor (WT) is a pediatric malignancy that occurs in embryonic kidney. Recently, a putative Wilms' tumor gene (WT1), located on chromosome 11p13, was isolated and characterized. We found constitutive expression of WT1 mRNA in eight out of 22 hematopoietic cell lines and seven out of 26 clinical samples which were derived from patients with various types of hematologic malignancies. WT1 mRNA was detected in four out of six myeloid cell lines, four out of 10 cases of acute myelocytic leukemia, three out of 15 lymphoid cell lines, one out of nine cases of lymphoid malignancies, and one out of six cases of chronic myelocytic leukemia in accelerated phase and blast crisis. One unclassified hematopoietic cell line and a case of myelodysplastic syndrome also expressed WT1 mRNA. No mutations were detectable in the cell lines by Southern blot analysis and a polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis in the four zinc finger domains of the WT1 gene. These results suggest that WT1 gene is expressed in several types of immature lymphoid or myeloid leukemia cells possibly without alterations of the WT1 gene.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321047

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  22 in total

Review 1.  Wilms' tumor gene WT1: its oncogenic function and clinical application.

Authors:  H Sugiyama
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

2.  Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma.

Authors:  K M Amin; L A Litzky; W R Smythe; A M Mooney; J M Morris; D J Mews; H I Pass; C Kari; U Rodeck; F J Rauscher
Journal:  Am J Pathol       Date:  1995-02       Impact factor: 4.307

3.  WT1 shRNA delivery using transferrin-conjugated PEG liposomes in an in vivo model of melanoma.

Authors:  Santiago Saavedra-Alonso; Pablo Zapata-Benavides; Ana Karina Chavez-Escamilla; Edgar Manilla-Muñoz; Diana Elisa Zamora-Avila; Moisés Armides Franco-Molina; Cristina Rodriguez-Padilla
Journal:  Exp Ther Med       Date:  2016-10-27       Impact factor: 2.447

4.  Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination.

Authors:  A Tsuboi; Y Oka; H Ogawa; O A Elisseeva; H Li; K Kawasaki; K Aozasa; T Kishimoto; K Udaka; H Sugiyama
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

5.  The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells.

Authors:  Hanfen Li; Yoshihiro Oka; Akihiro Tsuboi; Tamotsu Yamagami; Toru Miyazaki; Sei-ichi Yusa; Kotomi Kawasaki; Yukiko Kishimoto; Momotaro Asada; Hiroko Nakajima; Keisuke Kanato; Sumiyuki Nishida; Tomoki Masuda; Masaki Murakami; Naoki Hosen; Manabu Kawakami; Hiroyasu Ogawa; Fritz Melchers; Ichiro Kawase; Yusuke Oji; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

6.  Successful repeated treatment of acute myeloid leukemia in early relapse with gemtuzumab ozogamicin alone.

Authors:  Hiroko Tsunemine; Hiroshi Akasaka; Emiko Ishikawa Sakane; Kiminari Ito; Taiichi Kodaka; Takayuki Takahashi
Journal:  Int J Hematol       Date:  2013-12-01       Impact factor: 2.490

7.  Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Masaki Murakami; Manabu Hirai; Nobuhiko Tominaga; Hiroko Nakajima; Olga A Elisseeva; Tomoki Masuda; Akiko Nakano; Manabu Kawakami; Yusuke Oji; Kazuhiro Ikegame; Naoki Hosen; Keiko Udaka; Masaki Yasukawa; Hiroyasu Ogawa; Ichiro Kawase; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

Review 8.  Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia.

Authors:  Raajit Rampal; Maria E Figueroa
Journal:  Haematologica       Date:  2016-06       Impact factor: 9.941

9.  K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.

Authors:  B Douglas Smith; Yvette L Kasamon; Jeanne Kowalski; Christopher Gocke; Kathleen Murphy; Carole B Miller; Elizabeth Garrett-Mayer; Hua-Ling Tsai; Lu Qin; Christina Chia; Barbara Biedrzycki; Thomas C Harding; Guang Haun Tu; Richard Jones; Kristen Hege; Hyam I Levitsky
Journal:  Clin Cancer Res       Date:  2010-01-01       Impact factor: 12.531

Review 10.  Cancer immunotherapy targeting WT1 protein.

Authors:  Haruo Sugiyama
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.